Benzinga | Oct 5, 2020 08:08AM EDT

Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

LUNAR(r) lipids undetectable in plasma 48 hours following drug administration

ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4

Initial dosing of OTC-deficient patients at a U.S. clinical site expected in Q4